Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia

Drug and Alcohol Dependence

Volumn 133, Issue 2, 2013, Pages 529-534

  Treloar, Carla ^a   Rance, Jake ^a   Grebely, Jason ^b   Dore, Gregory J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HCV; Integrated care; Opioid substitution treatment; People who use drugs; Qualitative research

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; CONFIDENTIALITY; FEMALE; HEALTH CARE COST; HEALTH PERSONNEL ATTITUDE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MALE; OBSERVATIONAL STUDY; OPIATE SUBSTITUTION TREATMENT; PATIENT CARE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PRIVACY; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; SEMI STRUCTURED INTERVIEW;

HEPATITIS C VIRUS;

HCV; INTEGRATED CARE; OPIOID SUBSTITUTION TREATMENT; PEOPLE WHO USE DRUGS; QUALITATIVE RESEARCH;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CONFIDENTIALITY; FEMALE; HEALTH FACILITIES; HEALTH PERSONNEL; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; OPIATE SUBSTITUTION TREATMENT; PATIENT SATISFACTION; PRIVACY; PROFESSIONAL-PATIENT RELATIONS; SOCIAL STIGMA; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; TRANSPORTATION OF PATIENTS;

EID: 84887025378     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.07.023     Document Type: Article

References (33)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int. J. Drug Policy 2007, 18:352-358.
2. Ahern J., Stuber J., Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007, 88:188-196.
3. Alavi M., Grebely J., Micallef M., Dunlop A., Balcomb A., Day C., Treloar C., Bath N., Haber P., Dore G. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opiate substitution setting: the ETHOS study. Clin. Infect. Dis. 2013, 57(S2):S62-S69.
4. Australian Institute of Health and Welfare Alcohol and Other Drug Treatment Services in Australia 2010-11: Report on the National Minimum Data Set. Drug Treatment Series no 18. Cat no HSE 128 2012, AIHW, Canberra.
5. Braun V., Clarke V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3:77-101.
6. Bruggmann P., Litwin A. Models of care for the management of HCV among people who use drugs: one size does not fit all. Clin. Infect. Dis. 2013, 7(S2):S56-S61.
7. Dimova R., Zeremski M., Jacobson I., Hagan H., Des Jarlais D., Talal A. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin. Infect. Dis. 2013, 56:806-816.
8. Fraser S. Speaking addictions: substitution, metaphor and authenticity in newspaper representations of methadone treatment. Contemp. Drug Probl. 2006, 33:669-698.
9. Fraser S., Valentine K. Substance and Substitution: Methadone Subjects in Liberal Societies 2008, Palgrave Macmillan, Basingstoke.
10. Global Commission on Drug Policy The Negative Impact of the War on Drugs on Public Health: The Hidden Hepatitis C Epidemic 2013, Global Commission on Drug Policy, Rio de Janeiro.
11. Grebely J., Raffa J., Lai C., Krajden M., Kerr T., Fischer B., Tyndall M. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J. Viral Hepat. 2009, 16:352-358.
12. Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2013, (Epub ahead of print).
13. Harris J., McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual. Health Res. 2012, 22:810-824.
14. Harris K.J., Arnsten J., Litwin A. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J. Addict. Med. 2010, 4:20-26.
15. Harris M., Rhodes T., Martin A. Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting. Soc. Sci. Med. 2013, 83:19-26.
16. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injecting drug users: a review of the available evidence. Clin. Infect. Dis. 2009, 49:561-573.
17. Iversen J., Grebely J., Topp L., Wand H., Dore G., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011. J. Viral Hepat. 2013, (in press). 10.1111/jvh.12129.
18. Iversen J., Maher L. Australian Needle and Syringe Program National Data Report 2008-2012 2013, The Kirby Institute, The University of New South Wales.
19. Keane H. Foucault on methadone: beyond biopower. Int. J. Drug Policy 2009, 20:450-452.
20. Krook A., Stokka D., Heger B., Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur. Addict. Res. 2007, 13:216-221.
21. Litwin A., Harris K.J., Nahvi S., Zamor P., Soloway I., Tenore P., Kaswan D., Gourevitch M., Arnsten J. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J. Subst. Abuse Treat. 2009, 37:32-40.
22. Mehta S., Genberg B.L., Astemborsk J., Kavasery R., Kirk G.D., Vlahov D., Strathdee S., Thomas D. Limited uptake of hepatitis C treatment among injection drug users. J. Community Health 2008, 33:126-133.
23. Mol A. The Logic of Care: Health and the Problem of Patient Choice 2008, Routledge, Oxford and New York.
24. Rance J., Newland J., Hopwood M., Treloar C. The politics of place(ment): problematizing the provision of hepatitis C treatment within opiate substation clinics. Soc. Sci. Med. 2012, 74:245-253.
25. Strauss S., Munoz-Plaza C., Jose Tiburcio N., Astone-Twerell J., Des Jarlais D., Gwadz M., Hagan H., Osborne A., Rosenblum A. Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. J. Drug Issues 2008, 38:1161.
26. Strauss S., Munoz-Plaza C., Rosedale M., Rindskopf D., Lunievicz J. Enhancing drug treatment program staff's self-efficacy to support patients' HCV needs. J. Soc. Work Pract. Addict. 2011, 11:254-269.
27. Swan D., Long J., Carr O., Flanagan J., Irish H., Keating S., Keaveney M., Lanbert J., McCormick A., McKiernan S., Moloney J., Perry N., Cullen W. Barriers to and facilitators of hepatitis C testing, management and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010, 24:753-762.
28. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002, 67:117-123.
29. Talal A., Dimova R., Seewald R., Peterson R., Zeremski M., Perlman D., Des Jarlais D. Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. J. Subst. Abuse Treat. 2013, 44:115-119.
30. Tindal C., Cook K., Foster N. Theorising stigma and the experiences of injecting drug users in Australia. Aust. J. Prim. Health 2010, 16:119-125.
31. Treloar C., Fraser S. Hepatitis C treatment: increasing treatment uptake needs a critical view [Commentary]. Drug Alcohol Rev. 2009, 28:436-440.
32. Treloar C., Newland J., Rance J., Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J. Viral Hepat. 2010, 17:839-844.
33. Wilkinson M., Crawford V., Tippet A., Jolly F., Turton J., Sims E., Hekker M., Dalton J., Marley R., Foster G. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment. Pharmacol. Ther. 2009, 29:29-37.